Tranet al. identified CD8 T-cell responses against mutantKRAS G12D andHLA-C*08:02 in a patient with colorectal cancer, receiving a single-dose infusion of 1.48 × 1011 TILs (approximately 75% CD8 T cells) with durable regression of lung metastases with disease progression 9 months after treatment16. This evidence concerns the gene CD8A and colorectal cancer.